Ecthyma gangrenosum: survival with individualized antibiotic therapy.
Five burn patients with ecthyma gangrenosum were treated with gentamicin sulfate in an individualized aminoglycoside regimen. Dosages greater than the currently recommended 3 to 5 mg/kg/day were necessary and ranged from 15 to 30 mg/kg/day. These increased dosages cannot be used routinely but only as serum level data indicate the need. Four of the five patients survived their course of ecthyma gangrenosum. The single fatality received a much smaller dosage of gentamicin as compared with the other four patients. No ototoxic or nephrotoxic reactions were noted in any of the patients.
D000293:Adolescent; D002056:Burns / Q000150:complications; D002228:Carbenicillin / Q000627:therapeutic use; D002675:Child, Preschool; D004473:Ecthyma / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D005734:Gangrene / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D005839:Gentamicins / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007668:Kidney / Q000503:physiopathology; D011552:Pseudomonas Infections / Q000097:blood / Q000188:drug therapy*
D005839:Gentamicins; D002228:Carbenicillin